MedTrace Logo

Predictors of Opioid-Induced Respiratory Depression (OIRD)

NCT02473354 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-03-10

No results posted yet for this study

Summary

Purpose of the Study: (1) To classify an individual subject's ventilatory response in terms of respiratory depression to a bolus of remifentanil under normoxic and hyperoxic conditions. (2) Measurement of specific respiratory parameters to predict the opioid-induced respiratory depression (OIRD) response.

Conditions

  • Respiratory Depression

Interventions

DRUG

Remifentanil

The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.

DRUG

Oxygen

Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.

DRUG

Carbon dioxide

Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)

Sponsors & Collaborators

Principal Investigators

  • David MacLeod, MB BS · Duke Anesthesiology

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-04-29
Completion
2018-04-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02473354 on ClinicalTrials.gov